Perlis N, Krahn M, Alibhai S, Finelli A, Ritvo P, Bremner K, et al. Mp15–01 developing the bladder utility symptom scale: a multiattribute health state classification for bladder cancer. J Urol. 2014;4:191(4S).
Ciocan C, Pira E, Coggiola M, Franco N, Godono A, La Vecchia C, et al. Mortality in the cohort of talc miners and millers from Val Chisone, Northern Italy: 74 years of follow-up. Environ Res. 2022;203: 111865.
Article CAS PubMed Google Scholar
Boustead GB, Fowler S, Swamy R, Kocklebergh R, Hounsome L. Stage, grade and pathological characteristics of bladder cancer in the <scp>UK</scp>: <scp>B</scp>ritish Association of Urological Surgeons (<scp>BAUS</scp>) Urological Tumour Registry. BJU Int. 2014;113(6):924–30.
Teoh JY-C, Kamat AM, Black PC, Grivas P, Shariat SF, Babjuk M. Recurrence mechanisms of non-muscle-invasive bladder cancer—a clinical perspective. Nat Rev Urol 2022;19(5):280‒94.
Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Dominguez Escrig JL, et al. European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol. 2022;81(1):75–94.
Han MA, Maisch P, Jung JH, Hwang JE, Narayan V, Cleves A, et al. Intravesical gemcitabine for non-muscle invasive bladder cancer. Cochrane Database Syst Rev 2021;6(6):CD009294-CD. PubMed PMID: 34125951. eng.
Califf RM. Biomarker definitions and their applications. Exp Biol Med (Maywood, NJ). 2018;243(3):213–21. PubMed PMID: 29405771. eng.
Qiu S, Cai Y, Yao H, Lin C, Xie Y, Tang S, et al. Small molecule metabolites: discovery of biomarkers and therapeutic targets. Signal Transduct Target Ther 2023;8(1):132. PubMed PMID: 36941259. eng.
Donatti A, Canto AM, Godoi AB, da Rosa DC, Lopes-Cendes I. Circulating Metabolites as Potential Biomarkers for Neurological Disorders-Metabolites in Neurological Disorders. Metabolites 2020;10(10):389. PubMed PMID: 33003305. eng.
Hu H, Li Z, Chen J, Wang D, Ma J, Wang W, et al. P16 reactivation induces anoikis and exhibits antitumour potency by downregulating Akt/survivin signalling in hepatocellular carcinoma cells. Gut. 2010;60(5):710–21.
Rafatmanesh A, Behjati M, Mobasseri N, Sarvizadeh M, Mazoochi T, Karimian M. The survivin molecule as a double-edged sword in cellular physiologic and pathologic conditions and its role as a potential biomarker and therapeutic target in cancer. J Cell Physiol. 2019;235(2):725–44.
Jiang R, Yang Z-H, Luo D-H, Guo L, Sun R, Chen Q-Y, et al. Elevated apolipoprotein A-I levels are associated with favorable prognosis in metastatic nasopharyngeal carcinoma. Med Oncol 2014;31(8).
Marchioni M, Primiceri G, Ingrosso M, Filograna R, Castellan P, De Francesco P, et al. The clinical use of the Neutrophil to Lymphocyte Ratio (NLR) in urothelial cancer: a systematic review. Clin Genitourin Cancer. 2016;14(6):473–84.
Kwon H-C, Kim SH, Oh SY, Lee S, Lee JH, Choi H-J, et al. Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. Biomarkers. 2012;17(3):216–22.
Article CAS PubMed Google Scholar
Vartolomei MD, Porav-Hodade D, Ferro M, Mathieu R, Abufaraj M, Foerster B, et al. Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non–muscle-invasive bladder cancer (NMIBC): a systematic review and meta-analysis. Urol Oncol: Semin Orig Investig. 2018;36(9):389–99.
Wang Y, Wang Z-Q, Wang F-H, Lei X-F, Yan S-M, Wang D-S, et al. Predictive value of chemotherapy-related high-density lipoprotein cholesterol (HDL) elevation in patients with colorectal cancer receiving adjuvant chemotherapy: an exploratory analysis of 851 cases. Oncotarget 2016;7(35):57290–300. PubMed PMID: 27344180. eng.
Kamat AM, Hegarty PK, Gee JR, Clark PE, Svatek RS, Hegarty N, et al. ICUD-EAU International consultation on bladder cancer 2012: screening, diagnosis, and molecular markers. Eur Urol. 2013;63(1):4–15.
Page MJ, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, mulrow cd, et al. Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. Center for Open Science. 2020.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.
Yun SJ, Jo S-W, Ha Y-S, Lee O-J, Kim WT, Kim Y-J, et al. PFKFB4 as a prognostic marker in non-muscle-invasive bladder cancer. Urol Oncol: Semin Orig Investig. 2012;30(6):893–9.
Kim E-J, Lee Y-S, Kim Y-J, Kim M-J, Ha Y-S, Jeong P, et al. Clinical implications and prognostic values of Topoisomerase-II alpha expression in primary non–muscle-invasive bladder cancer. Urology. 2010;75(6):1516.e9-.e13.
Oderda M, Ricceri F, Pisano F, Fiorito C, Gurioli A, Casetta G, et al. Prognostic Factors Including Ki-67 and p53 in Bacillus Calmette-Guérin-Treated Non-Muscle-Invasive Bladder Cancer: A Prospective Study. Urol Int. 2013;90(2):184–90.
Article CAS PubMed Google Scholar
Bertz S, Otto W, Denzinger S, Wieland WF, Burger M, Stöhr R, et al. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer. Eur Urol. 2014;65(1):218–26.
Article CAS PubMed Google Scholar
Kim JH, Park J. Prognostic significance of heme oxygenase-1, S100 calcium-binding protein A4, and syndecan-1 expression in primary non–muscle-invasive bladder cancer. Hum Pathol. 2014;45(9):1830–8.
Article CAS PubMed Google Scholar
Mbeutcha A, Shariat SF, Rieken M, Rink M, Xylinas E, Seitz C, et al. Prognostic significance of markers of systemic inflammatory response in patients with non–muscle-invasive bladder cancer. Urol Oncol: Semin Orig Investig. 2016;34(11):483.e17-.e24.
Abufaraj M, Shariat SF, Haitel A, Moschini M, Foerster B, Chłosta P, et al. Prognostic role of N-cadherin expression in patients with non–muscle-invasive bladder cancer. Urol Oncol: Semin Orig Investig. 2017;35(5):264–71.
Vartolomei MD, Ferro M, Cantiello F, Lucarelli G, Di Stasi S, Hurle R, et al. Validation of neutrophil-to-lymphocyte ratio in a multi-institutional cohort of patients With T1G3 non–muscle-invasive bladder cancer. Clin Genitourin Cancer. 2018;16(6):445–52.
Ben Fradj MK, Ouanes Y, Hadj-Taeib S, Mrad Dali K, Bibi M, Jmal K, et al. Prognostic significance of plasma folate and cobalamin concentrations in non-muscle-invasive bladder cancer: a prospective cohort study. Cancer Investig. 2021;39(3):240–50.
Ding W, Gou Y, Sun C, Xia G, Wang H, Chen Z, et al. Ki-67 is an independent indicator in non–muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC. Urol Oncol: Semin Orig Investig. 2014;32(1):42.e13-42.e19.
Muramaki M, Miyake H, Terakawa T, Kumano M, Sakai I, Fujisawa M. Expression profile of E-cadherin and N-cadherin in non-muscle-invasive bladder cancer as a novel predictor of intravesical recurrence following transurethral resection. Urol Oncol: Semin Orig Investig. 2012;30(2):161–6.
Bhindi B, Hermanns T, Wei Y, Yu J, Richard PO, Wettstein MS, et al. Identification of the best complete blood count-based predictors for bladder cancer outcomes in patients undergoing radical cystectomy. Br J Cancer 2016;114(2):207–12. PubMed PMID: 26657651. Epub 12/10. eng.
Yasui M, Kawahara T, Izumi K, Yao M, Ishiguro Y, Ishiguro H, et al. Androgen receptor mRNA expression is a predictor for recurrence-free survival in non-muscle invasive bladder cancer. BMC cancer 2019;19(1):331. PubMed PMID: 30961575. eng.
Shang Z, Wang J, Wang X, Yan H, Cui B, Jia C, et al. Preoperative serum apolipoprotein A-I levels predict long-term survival in non-muscle-invasive bladder cancer patients. Cancer Manag Res 2018;10:1177–90. PubMed PMID: 29795989. eng.
Salah Fararjeh A, Al-Khader A, Al-Saleem M, Abu Qauod R. The prognostic significance of proteasome 26S subunit, non-ATPase (PSMD) genes for bladder urothelial carcinoma patients. Cancer Inform 2021;20:11769351211067692. PubMed PMID: 34992336. eng.
Quintero A, Alvarez-Kindelan J, Luque RJ, Gonzalez-Campora R, Requena MJ, Montironi R, et al. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder. J Clin Pathol 2006;59(1):83–8. PubMed PMID: 16394286. eng.
Margulis V, Lotan Y, Karakiewicz PI, Fradet Y, Ashfaq R, Capitanio U, et al. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. JNCI J Natl Cancer Inst. 2009;101(2):114–9.
Quintero A, Alvarez-Kindelan J, Luque RJ, Gonzalez-Campora R, Requena MJ, Montironi R, et al. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder. J Clin Pathol 2006;59(1):83–8. PubMed PMID: 16394286. Pubmed Central PMCID: 1860249.
Shariat SF, Passoni N, Bagrodia A, Rachakonda V, Xylinas E, Robinson B, et al. Prospective evaluation of a preoperative biomarker panel for prediction of upstaging at radical cystectomy. BJU Int. 2014;113(1):70–6 (PubMed PMID: 24053584).
Saint F, Le Frere Belda M-A, Quintela R, Hoznek A, Patard J-J, Bellot J, et al. Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guérin (BCG). Eur Urol. 2004;45(4):475–82.
López-Linares JC, García-Cubero MT, Coca M, Lucas S. A biorefinery approach for the valorization of spent coffee grounds to produce antioxidant compounds and biobutanol. Biomass Bioenergy. 2021;147: 106026.
Cormio L, Tolve I, Annese P, Saracino A, Zamparese R, Sanguedolce F, et al. Retinoblastoma protein expression predicts response to bacillus Calmette-Guérin immunotherapy in patients with T1G3 bladder cancer. Urol Oncol: Semin Orig Investig. 2010;28(3):285–9.
Sikic D, Breyer J, Hartmann A, Burger M, Erben P, Denzinger S, et al. High androgen receptor mRNA expression is independently associated with prolonged cancer-specific and recurrence-free survival in stage T1 bladder cancer. Transl Oncol 2017;10(3):340–5. PubMed PMID: 28342317. Epub 03/22. eng.
Ozyalvacli ME, Ozyalvacli G, Kocaaslan R, Cecen K, Uyeturk U, Kemahlı E, et al. Neutrophil-lymphocyte ratio as a predictor of recurrence and progression in patients with high-grade pT1 bladder cancer. Can Urol Assoc J = J l'Association Urol Can 2015;9(3–4):E126-E31. PubMed PMID: 25844098. eng.
Mano R, Baniel J, Shoshany O, Margel D, Bar-On T, Nativ O, et al. Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non–muscle-invasive bladder cancer. Urol Oncol: Semin Orig Investig. 2015;33(2):67.e1-.e7.
Zuiverloon TCM, Nieuweboer AJM, Vékony H, Kirkels WJ, Bangma CH, Zwarthoff EC. Markers predicting response to bacillus calmette-guérin immunotherapy in high-risk bladder cancer patients: a systematic review. Eur Urol. 2012;61(1):128–45.
Rausch S, Hennenlotter J, Todenhöfer T, Aufderklamm S, Schwentner C, Sievert K-D, et al. Impaired estimated glomerular filtration rate is a significant predictor for non–muscle-invasive bladder cancer recurrence and progression—introducing a novel prognostic model for bladder cancer recurrence. Urol Oncol: Semin Orig Investig. 2014;32(8):1178–83.
Luo X-L, Zhong G-Z, Hu L-Y, Chen J, Liang Y, Chen Q-Y, et al. Serum apolipoprotein A-I is a novel prognostic indicator for non-metastatic nasopharyngeal carcinoma. Oncotarget 2015;6(41):44037–48. PubMed PMID: 26503474. eng.
Wang X-P, Li X-H, Zhang L, Lin J-H, Huang H, Kang T, et al. High level of serum apolipoprotein A-I is a favorable prognostic factor for overall survival in esophageal squamous cell carcinoma. BMC cancer 2016;16:516. PubMed PMID: 27444612. eng.
Guo S, He X, Chen Q, Yang G, Yao K, Dong P, et al. The Effect of Preoperative apolipoprotein A-I on the prognosis of surgical renal cell carcinoma: a retrospective large sample study. Medicine 2016;95(12):e3147-e. PubMed PMID: 27015197. eng.
Tu H, Dinney CP, Ye Y, Grossman HB, Lerner SP, Wu X. Is folic acid safe for non-muscle-invasive bladder cancer patients? An evidence-based cohort study. Am J Clin Nutr 2018;107(2):208–16. PubMed PMID: 29529165. eng.
Yim M-S, Ha Y-S, Kim IY, Yun S-J, Choi YH, Kim W-J. HMOX1 is an important prognostic indicator of nonmuscle invasive bladder cancer recurrence and progression. J Urol. 2011;185(2):701–5.
Article CAS PubMed Google Scholar
Guo S, Wu X, Lei T, Zhong R, Wang Y, Zhang L, et al. The role and therapeutic value of Syndecan-1 in cancer metastasis and drug resistance. Front Cell Dev Biol 2022;9:784983. PubMed PMID: 35118073. eng.
Cao G, Zhang C, Tian X, Jing G, Zhou X, Yan T. circCEP128 Knockdown suppresses bladder cancer progression via regulating microRNA-515–5p/SDC1 axis. Cancer Manag Res 2021;13:2885–96. PubMed PMID: 33833571. eng.
Tambunan MP, Saraswati M, Umbas R, Mochtar CA, Hamid ARAH. E-cadherin expressions on bladder and its association with cancer progressivity: a retrospective cohort study. Afr J Urol 2022;28(1).
Mocchetti I. In vivo studies of the regulation of neuropeptide stores in structures of the rat brain. Neuropharmacology. 1987;26(7):855–62.
Comments (0)